Anti-Vascular Endothelial Growth Factor Therapeutics Industry Poised for Rapid Growth, Forecast to Touch $13.59 Billion by 2030 at 2.4% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the anti-vascular endothelial growth factor therapeutics market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Anti-Vascular Endothelial Growth Factor Therapeutics Market reach by 2030 starting from 2026 levels?
The anti-vascular endothelial growth factor therapeutics market size has seen slight expansion in recent years. It is anticipated to increase from $12.17 billion in 2025 to $12.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 1.6%. Key drivers for its historical growth include the approval of lucentis and eylea, the increasing prevalence of age-related macular degeneration, a rising incidence of diabetic retinopathy, developments in molecular biology related to angiogenesis inhibition, and the expansion of hospital ophthalmology services.
The anti-vascular endothelial growth factor therapeutics market is projected to experience consistent expansion over the upcoming years. This market is forecast to reach $13.59 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 2.4%. This anticipated growth during the forecast period is attributable to several factors, including the introduction of advanced anti-VEGF therapeutics, greater investment in precision oncology, an increase in biosimilar market penetration, rising healthcare spending across developing markets, and the use of combination therapies for retinal conditions. Key trends anticipated within the same forecast timeframe encompass the expanding utilization of anti-VEGF treatments in ophthalmology, the proliferation of targeted cancer therapies, the creation of biosimilar anti-VEGF medications, an aging global population boosting AMD treatments, and the broadening of outpatient and specialized clinical facilities.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
Which Drivers Are Influencing Long-Term Growth In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Looking ahead, a rise in the occurrence of ophthalmic diseases is anticipated to boost the expansion of the anti-vascular endothelial growth factor therapeutics market. This prevalence denotes the count or percentage of people in a particular population who have been identified with or show signs of specific eye ailments or disorders. Anti-vascular endothelial growth factor (VEGF) treatments are instrumental in lowering the incidence of ophthalmic diseases, as they effectively manage conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For example, data from August 2023, provided by the World Health Organization, an international public health body based in Switzerland, indicates that approximately 2.2 billion individuals worldwide experience near or distance vision impairment, with 1 billion of these people currently suffering from such impairment. Furthermore, within this affected group, 88.4 million individuals are afflicted with refractive error, 94 million have cataracts, 8 million are impacted by age-related macular degeneration, and roughly 3.9 million contend with diabetic retinopathy. Consequently, the rising prevalence of ophthalmic diseases is fueling the expansion of the anti-vascular endothelial growth factor therapeutics market.
Which Segments Are Driving Activity In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Which Trends Are Influencing The Development Of The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Leading firms in the anti-VEGF therapeutics market are increasingly establishing strategic alliances to expedite the progress, market introduction, and utilization of VEGF inhibitors. These alliances enable corporations to utilize diverse specializations, gain access to novel technologies, and broaden their footprint in the market. A case in point is the strategic collaboration formed in January 2025 by Teva Pharmaceuticals International GmbH, a Swiss subsidiary of Teva Pharmaceutical Industries focused on biosimilars and complex generics, with Klinge Biopharma GmbH and Formycon AG. This partnership aims to commercialize FYB203, a biosimilar of Eylea (aflibercept), across Europe (excluding Italy) and Israel. Through this agreement, Teva utilizes its existing commercial framework and distribution channels to enhance its standing in the anti-VEGF therapeutics market. Formycon AG is tasked with the development of FYB203, while Klinge Biopharma GmbH possesses the exclusive global rights for the product’s commercialization.
Which Key Players Are Driving Competition In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market are F. Hoffmann-La Roche AG, Pfizer Inc., Coherus BioSciences Inc., Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Anti-Vascular Endothelial Growth Factor Therapeutics Market During The Forecast Period?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2025. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Anti-Vascular Endothelial Growth Factor Therapeutics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp
Browse Through More Reports Similar to the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market 2026, By The Business Research Company
Anti Vascular Endothelial Growth Factor Therapeutics Market Report 2026
Tumor Necrosis Factor Inhibitor Drugs Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
